Annual Report 2015

Downloads Downloads
Share
Octapharma.com

Annual Report 2015

Contact

Annual Report 2015 It's in our blood
scroll down to view
Annual Report 2015 It's in our blood
scroll down to view
Annual Report 2015 It's in our blood
scroll down to view
Annual Report 2015 It's in our blood
scroll down to view
Annual Report 2015 It's in our blood
scroll down to view
Annual Report 2015 It's in our blood
scroll down to view

Octapharma is one of the largest human protein product manufacturers in the world, developing and producing human proteins from human plasma and human cell lines.

As a family-owned company, Octapharma believes in investing to make a difference in people’s lives and has been doing so since 1983; because it’s in our blood.

Octapharma is a family business dedicated to always going further to empower more patients to go further in their life adventure.

To learn more visit our corporate website
€1.5bn Revenue
€351m Operating income
>€240m Total investments
6,213 Employees

Developing a range of products for the safe and optimal use of human proteins

Haematology

Octapharma’s haematology portfolio comprises high purity plasma-derived and recombinant coagulation factor concentrates for patients with bleeding disorders.

Recombinant human coagulation factor VIII (rDNA), Nuwiq® (simoctocog alfa) is a purified protein for the treatment and prophylaxis of bleeding in all age groups with haemophilia A (congenital factor VIII [FVIII] deficiency).

High purity human factor VIII / von Willebrand factor (VWF) concentrate for prophylaxis and treatment of bleeding in patients with haemophilia A.

High purity human factor IX concentrate for the prophylaxis and treatment of bleeding in patients with haemophilia B.

High purity human VWF/FVIII concentrate with the native VWF/FVIII complex in physiological 1:1 ratio for the treatment of patients with von Willebrand disease and haemophilia A.

Immunotherapy

Octapharma’s immunotherapy portfolio comprises high purity human immunoglobulin products for the treatment of various immune mediated diseases and deficiencies through immunomodulation and immunoglobulin replacement therapy.

gammanorm® 16.5% (165 mg/ml) normal immunoglobulin for subcutaneous administration (SCIG). Liquid, ready-to-use SCIG.

octagam® 5% (50 mg/ml) normal intravenous immunoglobulin (IVIG). Liquid, ready-to-use IVIG.

octagam® 10% (100 mg/ml) normal intravenous immunoglobulin (IVIG). Liquid, ready-to-use IVIG.

rhesonativ® anti-D immunoglobulin for intramuscular administration.

Critical care

Octapharma’s critical care portfolio comprises human plasma and protein products for the treatment of critically ill or injured patients in intensive care and emergency settings.

Human albumin for restoration and maintenance of circulating blood volume.

Pharmaceutically licensed, solvent/detergent treated, prion reduced human plasma for transfusion. Standardised coagulation factors content.

High purity human antithrombin III concentrate for the treatment of coagulation disturbances in connection with inherited and acquired antithrombin deficiency.

Human prothrombin complex concentrate containing factors II, VII, IX, X, as well as protein C and protein S.

Chairman's introduction

Wolfgang Marguerre Chairman and Chief Executive of the Octapharma Group

Investing to make a difference It’s in our blood

The year 2015 has been another record-breaking year for Octapharma in which we reached sales in excess of €1.5 billion with a pre-tax profit of €363 million. This impressive performance is the result of the focused and disciplined efforts of more than 6,200 Octapharma employees globally. Together we are pushing forward with our shared objective of reaching €2 billion revenue within the next three years.

Our strong financial position with zero bank debt gives us the flexibility to invest our profits back into the company. Being profitable means we can better serve patients globally by investing in the things that make a real difference: making our factories bigger, expanding our fleet of plasma centres, developing new products and exploring novel recombinant technologies. We have also strengthened our regional presence in Latin America and South East Asia, as well as expanded our team in the US.

Being profitable means we can better serve patients globally by investing in the things that make a real difference.

Entering the recombinant business successfully was a major strategic objective of the company and I am pleased to see our first recombinant product, Nuwiq®, being approved in many countries worldwide including in the US, the EU, Canada and Australia. In 2015 we made an up-front investment of €80 million to become a minority shareholder of Glycotope, a company which has built a leading platform of “sugar” engineering tools that are designed to generate novel proteins with improved glycosylation patterns. Access to Glycotope’s GEX Cell Line Technology opens up a host of interesting and very promising opportunities which will accelerate the development of our recombinant pipeline. The collaboration with Glycotope will significantly strengthen our biotechnology business development and product portfolio providing significant growth opportunities for the future.

Octapharma is a company with a strong legacy in human blood plasma products, and we remain committed to developing our portfolio of products derived from plasma to fulfil patient needs around the world. We are continuing to invest aggressively in our plasma collection centres to allow us to meet the ever increasing global demand for our products. In 2015 we further increased our fleet of donation centres in the US and Europe which makes us increasingly self-sufficient in our plasma sourcing. We expect our new plasma testing laboratory in Charlotte will be inspected by the FDA during 2016 and we are looking forward to in-source all of our plasma testing activities in this lab.

Program 2019, which represents €400 million investment over four years, will double our production capacity and increase overall efficiencies. The program comprises 35 active projects, including a project for a new pilot plant in Vienna and capacity expansion projects in each of our European fractionation plants. I expect to see further focused efforts and cooperation in all projects in order to meet our ambitious strategic growth plans.

Octapharma is built on a promise to make a difference to the lives of patients, and I am proud to see that we are still working hard every single day to keep our promise.

A key driver in Octapharma’s growth in the coming years will come from panzyga®, our new third generation 10% IVIG, which will complement our star product octagam®. We are eagerly awaiting the registration of panzyga® in major markets during 2016. Panzyga® will initially be manufactured in our production plant in Lingolsheim, France. The name panzyga® means, “universal victorious protector” and I am convinced that this product will live up to its name and further enhance our immunotherapy portfolio.

Octapharma has always been committed to developing novel products to meet the unmet clinical needs of patients, especially those with rare conditions. In this endeavour, we are investing in a number of important clinical trials which are either ongoing or will begin in 2016, including the ongoing Nuwiq® PUP study (NuProtect), and personalised prophylaxis study (NuPreviq), the panzyga® CIDP study, and the personalised prophylaxis study with octanine®F (ProNINE). We are also eagerly anticipating commencing clinical trials with our new subcutaneous Ig product “Octanorm” in both PID and a neurological indication. Clinical trials have been completed for our new fibrinogen concentrate, which will be submitted for approval globally in 2016. Octapharma will be able to deliver additional treatment options for critically bleeding patients with this novel product, which will be an important addition to our critical care portfolio.

Octapharma is built on a promise to make a difference to the lives of patients, and I am proud to see that we are still working hard every single day to keep our promise. We have set ourselves ambitious growth targets in the coming years which will allow us to fulfil our mission of going further to empower more patients to go further in their life adventure. I am convinced we can achieve our aims by working together with continued diligence and determination.

To learn more visit our corporate website

Global overview

Growing our global scale We have built an international business with the scale to meet the increasing demands for plasma products

14 13 14 01 02 04 05 06 07 08 09 11 12 13 14 15 17 18 19 20 21 22 23 24 25 27 28 29 30 31 32 32 10 26 16 03